ANI Pharmaceuticals (ANIP) brings former AbbVie strategy chief onto board
Rhea-AI Filing Summary
ANI Pharmaceuticals, Inc. (ANIP) reported governance changes, appointing Henry Gosebruch to its Board of Directors effective August 19, 2026, with a term expiring at the 2027 annual meeting of stockholders. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector, including senior roles at Lakefront Biotherapeutics NV, Neumora Therapeutics, AbbVie and J.P. Morgan.
As a non-employee director, he will receive an initial restricted stock award valued at $525,000 under the company’s 2022 Stock Incentive Plan, vesting in three equal annual installments on the first, second and third anniversaries of joining the Board. ANI also disclosed that director Muthusamy “Samy” Shanmugam resigned from the Board effective immediately but will continue in his executive roles as Head of Research and Development and Chief Operating Officer of New Jersey Operations.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Initial restricted stock award grant date fair value: $525,000
Vesting schedule for restricted stock award: 3 equal installments
Board term expiration year: 2027
+3 more
6 metrics
Initial restricted stock award grant date fair value
$525,000
Restricted stock award to Henry Gosebruch upon joining the ANI Board
Vesting schedule for restricted stock award
3 equal installments
Award vests on the first, second and third anniversaries of joining the Board
Board term expiration year
2027
Gosebruch’s director term expires at ANI’s 2027 annual meeting of stockholders
Years of sector experience
over 30 years
Gosebruch’s corporate strategy, business development and finance experience
Transactions and investments completed under AbbVie leadership
more than 100
Deals completed by AbbVie’s Corporate Strategy Office while led by Gosebruch
Years of prior Board service by Shanmugam
five years
Thomas J. Haughey thanks Shanmugam for Board service over the past five years
Key Terms
restricted stock award, Amended and Restated 2022 Stock Incentive Plan, Rare Disease franchise, forward-looking statements, +1 more
5 terms
restricted stock award financial
"an initial grant of a restricted stock award under the Plan having a grant date fair value"
A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.
Amended and Restated 2022 Stock Incentive Plan financial
"As a non-employee director, Mr. Gosebruch is eligible to participate in the ANI"
Rare Disease franchise medical
"The Rare Disease franchise is a strong foundation, and I look forward to working"
forward-looking statements regulatory
"To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What board change did ANI Pharmaceuticals (ANIP) announce on August 19, 2026?
ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026. His term runs until the company’s 2027 annual meeting of stockholders, and he joins as a non-employee director with extensive biopharmaceutical strategy and M&A experience.
What equity compensation will Henry Gosebruch receive as an ANIP director?
Henry Gosebruch will receive an initial restricted stock award with a grant date fair value of $525,000 under ANI’s Amended and Restated 2022 Stock Incentive Plan. The award will vest in three equal installments on the first, second and third anniversaries of his joining the Board.
Did any ANI Pharmaceuticals (ANIP) director resign in this 8-K?
Yes. Muthusamy “Samy” Shanmugam resigned as a director effective immediately. He will continue in his executive management roles as Head of Research and Development and Chief Operating Officer of New Jersey Operations at ANI Pharmaceuticals.
How does ANI Pharmaceuticals describe its strategic focus in this announcement?
ANI Pharmaceuticals describes itself as a diversified biopharmaceutical company focused on sustainable growth through its Rare Disease business, Generics business, and Brands business. The release highlights its goal of becoming a leading Rare Disease company as it adds Henry Gosebruch to the Board.
What experience does Henry Gosebruch bring to the ANIP board?
Henry Gosebruch brings over 30 years of experience in corporate strategy, business development and finance. He has been CEO of Lakefront Biotherapeutics NV, previously led Neumora Therapeutics, and served as Executive Vice President and Chief Strategy Officer at AbbVie, overseeing more than 100 transactions and investments.
Is Henry Gosebruch eligible for ANIP’s stock incentive plan?
Yes. As a non-employee director, Henry Gosebruch is eligible to participate in ANI Pharmaceuticals’ Amended and Restated 2022 Stock Incentive Plan. His initial compensation includes a $525,000 restricted stock award that vests in three equal annual installments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): August 19, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||
Registrant's telephone number, including area code: (609 ) 759-1810
Not Applicable
(Former name or former address, if changed since last
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | ||||
On August 19, 2026, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company’s 2027 annual meeting of stockholders.
Mr. Gosebruch, 53, has served as Chief Executive Officer and a member of the board of directors of Lakefront Biotherapeutics NV, a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need, since May 2025. Prior to Lakefront, Mr. Gosebruch served as President and Chief Executive Officer of Neumora Therapeutics, Inc., a publicly traded neuroscience company, from July 2023 to February 2025. Prior to Neumora, he was Executive Vice President and Chief Strategy Officer at AbbVie Inc. from December 2015 to February 2023, where his responsibilities included corporate strategy, competitive intelligence, business development, and M&A. Prior to joining Abbvie in 2015, Mr. Gosebruch spent over 20 years at J.P. Morgan, where he was Co-Head of the North American M&A Group.
There is no arrangement or understanding between Mr. Gosebruch and any other person pursuant to which Mr. Gosebruch was selected to serve as a director of the Company, nor is Mr. Gosebruch a party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. As a non-employee director, Mr. Gosebruch is eligible to participate in the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the “Plan”). For his service on the Board, Mr. Gosebruch will receive compensation in accordance with the Company’s general policies for compensation of non-employee directors, including, without limitation, an initial grant of a restricted stock award under the Plan having a grant date fair value equal to $525,000 upon joining the Board, which will vest in three equal installments on the first, second and third anniversary of Mr. Gosebruch joining the Board.
On August 23, 2026, Muthusamy “Samy” Shanmugam informed the Board of his decision to resign as a director effective immediately. Mr. Shanmugam will remain in his executive management role as ANI’s Head of Research and Development and Chief Operating Officer of New Jersey Operations.
The Company issued a press release on August 24, 2026 announcing Mr. Gosebruch’s appointment to the Board and Mr. Shanmugam’s resignation. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated by reference herein.
| Item 9.01 | Exhibits. | ||||
(d)Exhibits
| Exhibit No. | Description | ||||
| 99.1 | Press Release, dated August 24, 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 24, 2026 | ANI PHARMACEUTICALS, INC. | |||||||
| By: | /s/ Stephen P. Carey | |||||||
| Name: | Stephen P. Carey | |||||||
| Title: | Senior Vice President Finance and Chief Financial Officer | |||||||
Exhibit 99.1
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –
PRINCETON, N.J., August 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector.
“We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. “His proven track record in corporate strategy and value-creating acquisitions is expected to strengthen our business development and capital allocation initiatives as we accelerate our transformation to become a leading Rare Disease company. We are delighted to welcome him to the Board, and look forward to his contributions,” he concluded.
“ANI has the management team, the commercial infrastructure and the balance sheet to take a meaningful next step in its evolution via additional business development,” said Mr. Gosebruch. “The Rare Disease franchise is a strong foundation, and I look forward to working with Nikhil, Tom and my fellow directors to help the Company execute the next steps in its transformation.”
Mr. Gosebruch has served as Chief Executive Officer of Lakefront Biotherapeutics NV (formerly Galapagos NV) since May 2025, where he is also a member of the Board of Directors. From July 2023 to February 2025, he served as President and Chief Executive Officer of Neumora Therapeutics, Inc., a publicly traded neuroscience company.
Prior to Neumora, from 2015 to 2023, Mr. Gosebruch was Executive Vice President and Chief Strategy Officer of AbbVie, where he built and led the company’s Corporate Strategy Office, spanning corporate strategy, competitive intelligence, business development and M&A, search and evaluation, alliance management, and AbbVie Ventures. Under his leadership, the group completed more than 100 transactions and investments, including AbbVie’s acquisition of Allergan. Earlier in his career, he spent more than 20 years at J.P. Morgan, most recently as Co-Head of North American M&A.
Mr. Gosebruch serves on the Advisory Board of the University of Pennsylvania Life Sciences & Management Program. He holds a B.S. in Economics from the Wharton School at the University of Pennsylvania and is a certified public accountant.
The Company also announced that Muthusamy (Samy) Shanmugam has notified the Board of his decision to resign as a director effective immediately. He will remain in his executive management role as ANI’s Head of Research and Development and Chief Operating Officer of New Jersey Operations.
Mr. Haughey continued, “I want to thank Samy for his dedicated Board service and valuable contributions over the past five years. We will continue to benefit from his insights and deep experience as a member of our executive leadership team.”
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s strategy; its expectations regarding its future operations, financial position or revenues, including its 2026 financial guidance; its expectations regarding its share repurchase program; the results and timing of the Company’s preclinical studies, clinical trials, regulatory submissions and regulatory approvals; the commercialization and anticipated sales of the Company’s products, including current and planned product launches and any additional product launches from the Company’s generic pipeline; the Company’s estimates of the market opportunity and addressable patient populations for its products; the expansion and execution capabilities of the Company’s sales force for acute gouty arthritis for Cortrophin Gel; the Company’s anticipated growth opportunities, including for Cortrophin Gel and ILUVIEN; the Company’s positioning for continued shareholder value creation; anticipated R&D developments and clinical trial advances; and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates.
Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company’s approved products, including Cortrophin Gel and ILUVIEN, to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; the Company’s ability to complete or achieve any or all of the intended benefits of acquisitions and investments, in a timely manner or at all; delays and disruptions in the production of the Company’s approved products; increased costs and potential loss of revenues if the Company needs to change suppliers due to the limited number of suppliers for its raw materials, active pharmaceutical ingredients, excipients, and other materials; delays and disruptions in the production of the Company’s approved products as a result of its reliance on single source third party contract manufacturing supply for certain of its key products, including Cortrophin Gel and ILUVIEN; delays or failure to obtain or maintain approvals by the FDA of the Company’s products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company’s products from both domestic and overseas sources due to supply chain disruptions or for any other reason, including increased costs due to tariffs or macroeconomic disruptions; the ability of the Company’s manufacturing partners to meet its product demands and timelines; the impact of changes or fluctuations in exchange rates; the Company’s ability to develop, license or acquire, and commercialize new products; the Company’s obligations in agreements under which it licenses, develops or commercializes rights to products or technology from third parties and its ability to maintain such licenses; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the Company’s ability to protect its intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the impact of any litigation to which the Company is, or may become, a party; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; the Company’s ability to maintain the services of its key executives and other personnel; and general business and economic conditions, such as inflationary pressures, geopolitical conditions.
More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com
Media Relations: Argot Partners
T: 212-600-1494
E: ani@argotpartners.com
Source: ANI Pharmaceuticals, Inc.